Information Provided By:
Fly News Breaks for August 1, 2019
VNDA
Aug 1, 2019 | 06:30 EDT
Citi analyst Joel Beatty upgraded Vanda Pharmaceuticals to Buy from Neutral with an unchanged price target of $19. The current stock price is undervaluing Vanda's "profitable" base business due to "very poor" investor sentiment related to pipeline agent tradipitant, Beatty tells investors in a research note titled "We Believe Sentiment Has Hit Rock Bottom." The analyst sees "limited downside to buying the stock now," with potential for a "simple course change on tradipitant to lead to immediate and significant upside." Either starting an animal toxicity study or discontinuing tradipitant development completely would add $4 per share, estimates Beatty.
News For VNDA From the Last 2 Days
There are no results for your query VNDA